Validation of the oral mucositis assessment scale in pediatric cancer

Lillian Sung, George A. Tomlinson, Mark L. Greenberg, Gideon Koren, Peter Judd, Sylvia Ota, Brian M. Feldman

Research output: Contribution to journalArticlepeer-review

39 Scopus citations

Abstract

Background. Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy. Methods. Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration. Results. Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003). Conclusions. The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.

Original languageEnglish
Pages (from-to)149-153
Number of pages5
JournalPediatric Blood and Cancer
Volume49
Issue number2
DOIs
StatePublished - Aug 2007
Externally publishedYes

Keywords

  • Mucositis
  • Oral mucositis assessment scale
  • Pediatric
  • Validation

Fingerprint

Dive into the research topics of 'Validation of the oral mucositis assessment scale in pediatric cancer'. Together they form a unique fingerprint.

Cite this